Biotechnology

Filter

Current filters:

None

Popular Filters

1964 to 1988 of 2254 results

Biogen Idec in deal to buy Stromedix

15-02-2012

S biotech firm Biogen Idec (Nasdaq: BIIB) has entered into a definitive agreement to acquire Stromedix,…

Biogen IdecBiotechnologyMergers & AcquisitionsStromedix

US FDA priority review for Truvada for reducing HIV risk

15-02-2012

The US Food and Drug Administration has accepted the supplemental New Drug Application and granted a…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

Valeant bags another company, Eyetech

14-02-2012

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says that it has agreed…

BiotechnologyEyetechMacugenMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

Regeneron ups Eylea forecast, posts 2011 results

14-02-2012

USA-based biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares leap 12% to $114.10 in…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneronResearch

Legal provisions take toll on Actelion

14-02-2012

Switzerland-based Actelion (ATLN: VX), Europe’s largest biotech company, this morning posted full-year…

ActelionBiotechnologyFinancial

US Rx cough/cold deal boosts Vernalis

14-02-2012

UK biotech firm Vernalis (LSE: VER) saw its share price rocket 28% to 25.2 pence last Friday, when the…

BiotechnologyLicensingNorth AmericaResearchRespiratory and PulmonaryTris PharmaVernalis

Kineret halts organ damage in inflammatory genetic disorder

13-02-2012

A new study shows that Kineret (anakinra), a drug developed by US biotech giant Amgen (Nasdaq: AMGN)…

AmgenBiotechnologyKineretPharmaceuticalRare diseasesResearch

Fitch backs FDA planned guidelines, saying they open the door to biosimilars

12-02-2012

Fitch Ratings believes the US Federal Drug and Administration's proposed biosimilar pathway regulations,…

BiotechnologyGenericsHospiraNorth AmericaRegulation

EMA guidelines on pharmacogenetics in evaluating pharmacokinetics of medicines

12-02-2012

The European Medicines Agency on Friday published a guideline advising pharmaceutical companies how to…

BiotechnologyEuropePharmaceuticalRegulationResearch

At last, draft guidance on biosimilars pathway from US FDA

10-02-2012

Coming somewhat behind European Union action, the US Food and Drug Administration late yesterday issued…

BiotechnologyGenericsNorth AmericaRegulation

Celgene makes $15 million investment in Acetylon

10-02-2012

US biotech Celgene (Nasdaq: CELG) will invest a total of $15 million in Acetylon Pharmaceuticals via…

Acetylon PharmaceuticalsBiotechnologyCelgeneFinancial

Amgen fails to get FDA advisory backing for extended use of Xgeva

09-02-2012

The world’s largest independent biotech firm, Amgen (Nasdaq: AMGN), has failed to convince a Food…

AmgenBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationXgeva

Positive Ph II results for Genzyme’s oral Gaucher drug

09-02-2012

French drug major Sanofi’s (Euronext: SAN) US subsidiary Genzyme yesterday revealed four-year follow-up…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

Elan back in the black, boosted by Tysabri

09-02-2012

Ireland headquartered biotech company Elan Corp (LSE: ELN) has reported its fourth-quarter 2011 results…

BiotechnologyElanFinancialTysabri

Amylin 4th-qtr loss widens on charges

07-02-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) reported that in loss for the fourth quarter of…

AmylinBiotechnologyBydureonByettaDiabetesFinancial

AusBiotech sets out stall on R&D tax incentive discussion paper

07-02-2012

Australian trade group AusBiotech has lodged a submission in response to the “Discussion Paper:…

Asia-PacificBiotechnologyFinancialResearch

Reinventing biopharma: Strategies for an evolving marketplace

07-02-2012

The biopharmaceutical industry today is facing a multifaceted “value challenge”. It is no longer…

BiotechnologyGlobalMarkets & MarketingPharmaceuticalPricingRegulation

Merck KGaA licenses pancreatic cancer drug from Threshold

06-02-2012

Merck Serono, a division of German pharma and chemical major Merck KGaA (MRK: DE) has signed a global…

BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceuticalThreshold Pharmaceuticals

Sobi and Biogen Idec flesh out details of hemophilia programs

06-02-2012

Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) and US biotech company Biogen Idec (Nasdaq: BIIB)…

Biogen IdecBiotechnologyCardio-vascularLicensingPharmaceuticalSwedish Orphan Biovitrum

Genfit’s GFT505 improves insulin sensitivity

05-02-2012

French biotech firm Genfit (Alternext: ALGFT) says that its leading drug candidate GFT505 in a Phase…

BiotechnologyDiabetesGenfitResearch

EMA planning fundamental change in pharmacovigilance rules

03-02-2012

The European Medicines Agency, together with the European Union member states and the European Commission,…

BiotechnologyEuropePharmaceuticalRegulation

2011 financial briefs for Alkermes, Allergan, Gilead and Vertex

03-02-2012

Among the plethora of financial results being reported by US biotech and pharmaceutical companies were…

AlkermesAllerganBiotechnologyFinancialGilead SciencesPharmaceuticalVertex

Biotech deal-making off to a strong start in 2012, says Burrill

02-02-2012

Swiss drug major Roche's hostile $5.7 billion bid for the tools and sequencing systems company Illumina…

BiotechnologyFinancialLicensingMergers & AcquisitionsNorth America

1964 to 1988 of 2254 results

Back to top